IL24 and prostate carcinoma: conducted a study wherein they demonstrated a more potent bystander effect of Ad5‐M7S (a genetically engineered IL‐24 cytokine with enhanced stability and secretion capability) compared with wild‐type adenovirus carrying IL‐24 in melanoma and prostate cancer xenograft models (Pradhan et al. 2022).